论文部分内容阅读
目的 探讨造血干细胞移植治疗儿童白血病及恶性肿瘤的疗效。方法 采用造血干细胞移植治疗儿童白血病及实体瘤 17例 ,其中ALL 8例 ,AML 4例 ,CML 2例 ,淋巴瘤 1例 ,神经母细胞肿瘤 1例 ,性腺外生殖细胞肿瘤 1例。异基因造血干细胞移植 10例 ,自体造血干细胞移植 7例。结果 获得植入的 9例异基因造血干细胞移植患者造血恢复(WBC >1× 10 9/L)平均时间为 2 1 7d ,自体造血干细胞移植患者造血恢复平均时间为 16d。 8例异基因造血干细胞移植患者均使用了相似的方案 (Cy +TBI +VP16 +MeCCNU) ,均获得植入。在 5 /10异基因骨髓移植长期存活的病例中 ,3例为HLA不相合同胞。结论 HLA不相合异基因造血干细胞移植对于难治性和复发的白血病是一个可以选择的办法
Objective To investigate the therapeutic effect of hematopoietic stem cell transplantation on childhood leukemia and malignant tumors. Methods Seventeen children with leukemia and solid tumors were treated with hematopoietic stem cell transplantation. There were 8 cases of ALL, 4 cases of AML, 2 cases of CML, 1 case of lymphoma, 1 case of neuroblastoma and 1 case of gonadal germ cell tumor. Allogeneic hematopoietic stem cell transplantation in 10 cases, autologous stem cell transplantation in 7 cases. Results The average time for hematopoietic recovery (WBC> 1 × 10 9 / L) in 9 patients with allogeneic hematopoietic stem cell transplantation was 21 7 days. The mean time for hematopoietic recovery in patients with autologous hematopoietic stem cell transplantation was 16 days. A similar protocol (Cy + TBI + VP16 + MeCCNU) was used in all 8 patients with allogeneic hematopoietic stem cell transplantation and both received implantation. Of the 5/10 long-term allogeneic bone marrow transplant survival cases, 3 were HLA-incompatible siblings. Conclusions HLA-incompatible allogeneic hematopoietic stem cell transplantation is an alternative to refractory and relapsed leukemia